Evidence map›Paper›PMID 41202089›Full record

SynthesisPloS one2025

Global trends in the proportion of macrolide-resistant Mycobacterium Species: A systematic review and meta-analysis.

Saeid Sadeghi Ghazi Chaki, Saeed Babaie Pirsoltan, Masoumeh Beig, Tahereh Navidifar, Elnaz Parvizi, Maryam Mofid, Narges Golab, Mohammad Sholeh

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Saeid Sadeghi Ghazi ChakiDepartment of Microbial Biotechnology, School of Biology and Center of Excellence in Phylogeny of Living Organisms, College of Science, University of Tehran, Tehran, Iran.
Saeed Babaie PirsoltanDepartment of Biology, Faculty of Convergent Science and Technology, Sciences and Research Branch, Islamic. Azad University, Rasht, Iran.
Masoumeh BeigDepartment of Bacteriology, Pasteur Institute of Iran, Tehran, Iran.
Tahereh NavidifarDepartment of Basic Sciences, Shoushtar Faculty of Medical Sciences, Shoushtar, Iran.
Elnaz ParviziDepartment of Microbiology, Science and Research Branch, Islamic Azad University, Tehran, Iran.
Maryam MofidSchool of Medicine, Hamadan University of Medical Science, Hamadan, Iran.
Narges GolabDepartment of Microbiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Mohammad SholehDepartment of Bacteriology, Pasteur Institute of Iran, Tehran, Iran.ORCID https://orcid.org/0000-0003-1748-7225

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMacrolide resistance in Mycobacterium species is an emerging global problem, complicating treating non-tuberculous mycobacteria (NTM) and Mycobacterium tuberculosis. Understanding global resistance patterns is essential to improve treatment strategies and reduce morbidity and mortality.

objectiveThis study aimed to investigate macrolide resistance prevalence, distribution, and trends among Mycobacterium species in different world regions.

methodsA comprehensive search of Scopus, PubMed, Web of Science, and EMBASE (2015-2023) assessed study quality using JBI guidelines. Resistance proportions were calculated with a random-effects model, and additional meta-regression and subgroup analyses explored variations and trends. Statistical analyses were conducted using R and the metafor package.

resultsOut of 5,718 records, 41 studies across 17 countries were included. Azithromycin resistance was reported in 17 reports (3 Studies), with 156 resistant isolates among 715 tested, yielding a pooled rate of 29.0% (95% CI: 19.5-40.7%). Clarithromycin resistance, assessed in 76 reports (40 Studies), included 1,071 resistant isolates among 3,923 tested, with a pooled rate of 30.5% (95% CI: 23.7-38.2%). Erythromycin resistance was reported in 17 reports (3 Studies), with 350 resistant isolates among 752 tested, giving a pooled rate of 50.3% (95% CI: 37.5-62.9%). Meta-regression revealed a significant upward trend in azithromycin resistance over time (r = 0.558, p = 0.005).

conclusionThese findings underscore the need for targeted, region- and species-specific interventions to combat rising macrolide resistance in Mycobacterium species effectively.

Indexed as

Anti-Bacterial AgentsDrug Resistance, BacterialMacrolidesMycobacteriumMycobacterium Infections, NontuberculousAzithromycinGlobal HealthHumansMicrobial Sensitivity TestsNontuberculous MycobacteriaAnti-Bacterial AgentsAzithromycinMacrolides

Identifiers

PMID41202089
PMCPMC12594324

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.